Search Results - "patents"
Suggested Topics within your search.
Suggested Topics within your search.
- International law 13
- Medicine 12
- Research & information: general 12
- Copyright law 11
- Intellectual property law 10
- Technology: general issues 10
- Economic systems & structures 8
- History of engineering & technology 8
- International economic & trade law 8
- Materials science 8
- Patents law 8
- Economics 7
- Law 7
- Biology, life sciences 6
- Chemistry 6
- Entertainment & media law 6
- History 6
- History of science 6
- IT Law, Media Law, Intellectual Property 6
- Impact of science & technology on society 6
- Information technology 6
- International relations 6
- Law and legislation 6
- Mass media 6
- Patent medicines 6
- Physics 6
- Biotechnology 5
- Philosophy 5
- Property Law 5
- Sociology 5
-
1221
Antisense RNA Design, Delivery, and Analysis
Published 2022Table of Contents: “…Introduction and History of the Chemistry of Nucleic Acids Therapeutics -- Antisense RNA Therapeutics: A Brief Overview -- Design of Bifunctional Antisense Oligonucleotides for Exon Inclusion -- Design and Delivery of SINEUP: A New Modular Tool to Increase Protein Translation -- How to Design U1 snRNA Molecules for Splicing Rescue -- Conjugation of Nucleic Acids and Drugs to Gold Nanoparticles -- Determination of Optimum Ratio of Cationic Polymers and Small Interfering RNA with Agarose Gel Retardation Assay -- Generation of Protein-Phosphorodiamidate Morpholino Oligomer Conjugates for Efficient Cellular Delivery via Anthrax Protective Antigen -- Development and Use of Cellular Systems to Assess and Correct Splicing Defects -- Modeling Splicing Variants Amenable to Antisense Therapy by Use of CRISPR-Cas9-Based Gene Editing in HepG2 Cells -- In Vitro Models for the Evaluation of Antisense Oligonucleotides in Skin -- In Vitro Delivery of PMOs in Myoblasts by Electroporation -- Rapid Determination of MBNL1 Protein Levels by Quantitative Dot Blot for Evaluation of Antisense Oligonucleotides in Myotonic Dystrophy Myoblasts -- Evaluation of Exon Skipping and Dystrophin Restoration in In Vitro Models of Duchenne Muscular Dystrophy -- Generation of Human iPSC-Derived Myotubes to Investigate RNA-Based Therapies In Vitro -- Eye on a Dish Models to Evaluate Splicing Modulation -- Establishment of In Vitro Brain Models for AON Delivery -- Considerations for Generating Humanized Mouse Models to Test Efficacy of Antisense Oligonucleotides -- Generation of Humanized Zebrafish Models for the In Vivo Assessment of Antisense Oligonucleotide-Based Splice Modulation Therapies -- Use of Small Animal Models for Duchenne and Parameters to Assess Efficiency upon Antisense Treatment -- In Vivo Models for the Evaluation of Antisense Oligonucleotides in Skin -- Delivery of Antisense Oligonucleotides to the Mouse Retina -- Delivery of Antisense Oligonucleotides to the Mouse Brain by Intracerebroventricular Injections -- Intrathecal Delivery of Therapeutic Oligonucleotides for Potent Modulation of Gene Expression in the Central Nervous System -- Preclinical Safety Assessment of Therapeutic Oligonucleotides -- Preclinical Evaluation of the Renal Toxicity of Oligonucleotide Therapeutics in Mice -- Protocol for Isolation and Culture of Mouse Hepatocytes (HCs), Kupffer Cells (KCs), and Liver Sinusoidal Endothelial Cells (LSECs) in Analyses of Hepatic Drug Distribution -- Patent Considerations When Embarking on New Antisense Drug Programs.…”
Link to Metadata
Electronic eBook -
1222
Understanding the U.S. Economy for Racial Healing
Published 2023Connect to this object online.
Book -
1223
Molecular Mechanism of Congenital Heart Disease and Pulmonary Hypertension
Published 2020Table of Contents: “…PART I: Basic Science of Pulmonary Development and Pulmonary Arterial Disease -- 1 Perspective for Part I -- 2 The alveolar stem cell niche of the mammalian lung -- 3 Lung development and Notch signalling -- 4 Specialized smooth muscle cell progenitors in pulmonary hypertension -- 5 Diverse Pharmacology of Prostacyclin Mimetics: Implications for Pulmonary Hypertension -- 6 Endothelial-to-mesenchymal transition in pulmonary hypertension -- 7 Extracellular vesicles, MicroRNAs and Pulmonary Hypertension -- 8 Roles of Tbx4 in the lung mesenchyme for airway and vascular development -- 9 A lacZ reporter transgenic mouse line revealing the development of pulmonary artery -- 10 Roles of stem cell antigen-1 in the pulmonary endothelium -- 11 Morphological characterization of pulmonary microvascular disease in bronchopulmonary dysplasia caused by hyperoxia in newborn mice -- 12 Involvement of CXCR4 and stem cells in a rat model of pulmonary arterial hypertension -- 13 Ca2+ signal through inositol trisphosphate receptors for cardiovascular development and pathophysiology of pulmonary arterial hypertension -- PART II: Abnormal pulmonary circulation in the developing lung and heart -- 14 Perspective for Part II -- 15 Pathophysiology of Pulmonary Circulation in Congenital Heart Disease -- 16 Development of Novel Therapies for Pulmonary Hypertension by Clinical Application of Basic Research -- 17 Using Patient-Specific Induced Pluripotent Stem Cells to Understand and Treat Pulmonary Arterial Hypertension -- 18 Modeling pulmonary arterial hypertension using induced pluripotent stem cells -- 19 Dysfunction and restoration of endothelial cell communications in Pulmonary Arterial Hypertension: Therapeutic implications -- 20 Inflammatory Cytokines in the Pathogenesis of Pulmonary Arterial Hypertension -- 21 Genotypes and Phenotypes of Chinese Pediatric Patients with Idiopathic and Heritable Pulmonary Arterial Hypertension- Experiences from A Single Center -- 22 Fundamental Insight into Pulmonary Vascular Disease : Perspectives from Pediatric PAH in Japan -- 23 Risk stratification in paediatric pulmonary arterial hypertension -- 24 The Adaptive Right Ventricle in Eisenmenger Syndrome: Potential Therapeutic Targets for Pulmonary Hypertension -- 25 Impaired right coronary vasodilator function in pulmonary hypertensive rat assessed by in vivo synchrotron microangiography -- 26 Relationship between mutations in ENG and ALK1 gene and the affected organs in hereditary hemorrhagic telangiectasia -- 27 A genetic analysis for patients with pulmonary arterial hypertension -- 28 Evaluation and visualization of right ventricle using three dimensional echocardiography -- 29 Pulmonary hypertension associated with post-operative Tetralogy of Fallot -- 30 Microscopic Lung Airway Abnormality and Pulmonary Vascular Disease Associated with Congenital Systemic to Pulmonary Shunt -- 31 Respiratory syncytial virus infection in infants with heart and lung diseases -- PART III: Ductus arteriosus: bridge over troubled vessels -- 32 Perspective for Part III -- 33 The ductus arteriosus, a vascular outsider, in relation to the pulmonary circulation -- 34 Molecular, genetic, and pharmacological modulation of the ductus arteriosus: KATP channels as novel drug targets -- 35 New mediators in the biology of the ductus arteriosus: Lessons from the chicken embryo -- 36 Constriction of the Ductus Arteriosus with KATP Channel Inhibitors -- 37 New insights on how to treat patent ductus arteriosus -- 38 Antenatal Administration of Betamethasone Contributes to Intimal thickening of the Ductus Arteriosus -- 39 Prostaglandin E-EP4-mediated fibulin-1 up-regulation plays a role in intimal thickening of the ductus arteriosus -- 40 Transcriptional profiles in the chicken ductus arteriosus during hatching -- 41 Inhibition of Cyclooxygenase Contracts Chicken Ductus Arteriosus -- 42 Prostaglandin E2 receptor EP4 inhibition constricts the rat ductus arteriosus -- 43 Dilatation of the Ductus Arteriosus by Diazoxide in Fetal and Neonatal Rats -- 44 The Effect of Long-term Administration of Plostaglandin E1 on Morphological Changes in Ductus Arteriosus -- 45 Significance of SGK1 as a protein kinase transcriptionally regulated by ALK1 signaling in vascular endothelial cells -- 46 Fabrication of Implantable Human Arterial Graft by Periodic Hydrostatic Pressure -- 47 Optimum preparation of Candida albicans cell wall extra (CAWE) for the mouse model of Kawasaki disease -- PART IV: Development and Regeneration of the Cardiovascular System -- 48 Perspective for Part IV -- 49 Advances in the second heart field -- 50 Novel cardiac progenitors for all components of the heart except for the right ventricle -- 51 Regional and TBX5-dependent gene expression in the atria: Implications for pulmonary vein development and atrial fibrillation -- 52 The Endocardium as a Master Regulator of Ventricular Trabeculation -- 53 The Role of Alternative mRNA Splicing in Heart Development -- 54 Progress in the Generation of Multiple Lineage Human-iPSC-derived 3D Engineered Cardiac Tissues for Cardiac Repair -- 55 Quantification of contractility in stem cell derived cardiomyocytes -- 56 A neurotrophic factor receptor GFRA2, a specific surface antigen for cardiac progenitor cells, regulates the process of myocardial compaction -- 57 Cardiac cell specification and differentiation by the defined factors -- 58 A Temporo-Spatial Regulation of Sema3c is Essential for Interaction of Progenitor Cells during Cardiac Outflow Tract Development -- 59 Spatiotemporally restricted developmental alterations in the anterior and secondary heart fields cause distinct conotruncal heart defects -- 60 Significance of transcription factors in the mechanisms of great artery malformations -- 61 The different c-kit expression in human induced pluripotent stem (iPS) cells between with feeder cells and without feeder cells -- 62 Establishment of induced pluripotent stem cells from immortalized B cell lines and their differentiation into cardiomyocytes -- 63 Establishment of an in vitro LQT3 model, using induced pluripotent stem cells from LQT3 patient-derived cardiomyocytes -- 64 Genetic Assessments for clinical courses of Left ventricle noncompaction -- 65 Elucidating the pathogenesis of congenital heart disease in the era of next-generation sequencing.…”
Link to Metadata
Electronic eBook -
1224
-
1225
-
1226
PELAKSANAAN PEMBEBANAN HAK ATAS PATEN SEBAGAI OBJEK JAMINAN FIDUSIA
Published 2022Link Metadata
Book -
1227
Drafting eligible biotech and immunotherapy claims
Published 2019Connect to this object online.
Book -
1228
-
1229
-
1230
-
1231
-
1232
-
1233
-
1234
-
1235
Retrospective analysis of drug eruption in 440 cases
Published 2020Connect to this object online.
Book -
1236
-
1237
-
1238
-
1239
-
1240